| CPC A61K 31/658 (2023.05) [A61K 9/7084 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/32 (2013.01)] | 21 Claims |
|
1. A pharmaceutical composition comprising tetrahydrocannabinol (THC), in a dosage form for transdermal delivery wherein the pharmaceutical composition comprises:
a concentration of THC selected from the group consisting of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, and about 15% w/w;
about 5% to about 20% w/w of a solvent comprising propylene glycol;
about 1% to about 20% w/w of a penetration enhancer comprising oleic acid;
about 0.1% to about 0.7% w/w of butylated hydroxytoluene;
about 2% to about 15% w/w of at least one suspending agent comprising silicon dioxide;
about 0.1% to about 20% w/w of polyvinylpyrrolidone; and
about 50% to about 80% w/w of a silicone pressure sensitive adhesive,
wherein the pH of the composition is maintained at approximately 4.0 to 8.0, wherein the pharmaceutical composition is in the form of a transdermal matrix patch,
further wherein the pharmaceutical composition provides a constant rate of delivery of the active components of the transdermal matrix patch in a therapeutic range in a patient over 7 days.
|